Sea2Sky Advisory

A biopharma consulting company

Leverage deep, hands-on R&D experience and connectivity to address your critical drug development challenges.

Company

  • In- and out-licensing strategies

  • Pitch deck development

  • R&D organizational builds.

Portfolio

  • Indication and disease area assessments

  • Internal portfolio prioritization

Assets

  • Development options and decision matrices (Go / No Go)

  • Risk assessments

  • Integrated, IND to PoC development planning

Skier on mountain, looking off to a peak
Topography

What makes Sea2Sky Advisory different?

Drug development is a set of complex risk-based trade-offs.

Leveraging deep drug development experience across multiple therapeutic areas and across all major modalities we will work with you to understand your drivers and customize our recommendations accordingly. 

⇓

The Sea2Sky Advisory approach builds from a foundation of asset MoA, preclinical datasets and patient level data, up through aggregate datasets and analytics.

⇓

Our Development Guidance and Advice is Practical and Hands-on. There is no template for your challenges and there won’t be a template for the solutions.

Expert drug development guidance and advice to complement your existing R&D team

Innovative End to End drug development advice and strategies

Planning and then managing through critical R&D investment decisions and asset inflection points

Alpine Climbers walking down from a peak

Indications

  • Hematology (malignant / non-malignant)

  • Oncology / Immuno-Oncology

  • Cardiovascular

  • Fibrosis

  • Ex / in vivo CAR

  • Protein degradation

  • Small / large molecules

Platforms

Jonathan Leith Profile Image

About Sea2Sky Advisory principal Jonathan Leith, PhD

Deep, hands on drug development experience: 

  • Most recently accountable for >30 IND-to-PoC assets across hematology, oncology, in / ex vivo cell therapy; prior experience in gene therapy, cardiovascular and virology. 

  • Drove >10 INDs, 5 PoCs, 5 pivotal designs, 2 NME approvals, multiple indication expansions and HTA approvals.  

  • Key R&D partner to business development on multiple assessments and acquisitions 

C suite connectivity with biopharma, biotech and venture capital

  • Trusted to provide unvarnished truths with practical and thoughtful R&D perspectives. 

Builder of high performing R&D organizations:

  • Developed and implanted translational trouble-shooting team (Clinical Mechanisms)

  • Advised on complex R&D restructurings and org challenges.

Topography

Contact